Show
Sort by
-
EPOS2020/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP
-
- Journal Article
- A2
- open access
European biologic training course for type 2 inflammation by EUFOREA in 2024 : key facts and lessons learned
-
- Journal Article
- A1
- open access
Dupilumab response onset, maintenance, and durability in patients with severe CRSwNP
-
- Journal Article
- A1
- open access
Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps : SYNAPSE 24‐week treatment‐free follow‐up
-
- Journal Article
- A1
- open access
Clinical benefits with 300 IR HDM SLIT tablet in Europeans with house dust mite allergic rhinitis : post hoc analysis of a large phase 3 trial
-
- Journal Article
- A1
- open access
EUFOREUM Berlin 2023 : optimizing care for type 2 inflammatory diseases from clinic to AI : a pediatric focus
-
- Journal Article
- A1
- open access
EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care
-
- Journal Article
- A1
- open access
Consensus criteria for chronic rhinosinusitis disease control : an international Delphi Study
-
EPOS/EUFOREA update on indication and evaluation of biologics in chronic rhinosinusitis with nasal polyps 2023
-
- Journal Article
- A2
- open access
Evaluation of skin prick location on the forearm using a novel skin prick automated test device